CNS Biomarker Market Size at $6.5 billion in 2024, Forecasted to Grow Significantly

Global central nervous system (CNS) Biomarker market was valued at $6.5 billion in 2024 and is growing at a CAGR of 8.6% during the forecast period (2025-2035). The market growth is driven by the rising prevalence of neurological disorders (Alzheimer's, Parkinson's, MS), aging populations, and demand for early, personalized diagnosis, with North America leading, fueled by tech advancements (AI, omics) in biomarker discovery for drug development and monitoring. Its key factors include technological breakthroughs, increased research, strategic collaborations, growing awareness, and the shift towards precision medicine, despite challenges like high costs.

Browse the full report description of “Central Nervous System (CNS) Biomarker Market Size, Share & Trends Analysis Report by Application (Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others) by Type (Safety Biomarker, Efficacy Biomarker, Predictive Biomarker, Prognostic Biomarker, and Validation Biomarker) and by End User (Diagnostic Labs, Hospitals and Clinics, and Research Centers) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/central-nervous-system-cns-biomarkers-market

Moreover, the rising prevalence of neurological and neuropsychiatric disorders, including motion sickness, nausea, and vertigo, underscores the necessity for effective diagnostics and treatment monitoring. This recognition of CNS disorders is propelling the demand for biomarkers to inform therapy, thus fueling market growth. For instance, in 2025, Vanda Pharmaceuticals received FDA approval for NEREUS (tradipitant), the first new pharmacologic treatment for motion sickness in over 40 years. This oral neurokinin-1 (NK-1) receptor antagonist demonstrates significant efficacy in reducing vomiting induced by motion, supported by robust data from three pivotal clinical trials. Results show that NEREUS reduced vomiting incidence significantly compared to placebo, with reductions of over 50-70%. Recognized as a critical factor affecting military operations since World War II, motion sickness has prompted new antiemetic therapies to ensure operational readiness. The approval of NEREUS not only validates its pharmacological profile but also encourages further development of NK-1 antagonists for related conditions, including gastroparesis and nausea induced by GLP-1 receptor agonists.

Key Innovators Advancing Central Nervous System (CNS) Biomarker Development

Prominent companies in the central nervous system (CNS) biomarker sector, including Bio-Rad Laboratories, Hoffmann-La Roche AG, Merck KGaA, Siemens Healthineers, and Thermo Fisher Scientific, are contributing to the development of advanced healthcare solutions. Their initiatives span areas such as telemedicine, electronic health records, remote patient monitoring, and AI-assisted clinical tools. These efforts are enhancing clinical research capabilities and supporting the broader adoption of data-driven healthcare practices globally.

• In January 2026, Headlamp Health introduced Lumos AI, a new decision-support platform aimed at enhancing precision in neuroscience drug development. Unlike traditional AI tools that focus on workflow automation, Lumos AI utilizes clinical logic and pattern recognition to analyze biological, behavioral, and clinical signals, allowing development teams to make more informed decisions earlier in the drug development process.
• In January 2026, OPM and Ksilink collaborated to test the Nanocyclix chemical library using cell models from patients with serious central nervous system diseases. This partnership aims to leverage Ksilink's expertise in high-throughput phenotypic screening alongside OPM's focus on precision medicine for treating resistant and metastatic cancers, enabling the identification of new therapeutic targets and molecules.
• In January 2025, New biomaterial offers central nervous system injuries and neurodegenerative diseases like Alzheimer's and Parkinson's. Developed by researchers at Keele University and the University of Bath, this 3D piezoelectric cellulose composite serves as a scaffold for delivering neural stem cells to injury sites, potentially enhancing the recovery of motor, sensory, and cognitive functions. This advancement could reshape treatment options for patients with life-altering CNS injuries, a significant medical challenge globally.

Market Coverage

• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
  • By Application
  • By Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bio-Rad Laboratories, Hoffmann-La Roche AG, Merck KGaA, Siemens Healthineers, Thermo Fisher Scientific, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Central Nervous System (CNS) Biomarker Market Report Segment

By Application

• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

By Type

• Safety Biomarker
• Efficacy Biomarker
• Predictive Biomarker
• Prognostic Biomarker
• Validation Biomarker

By End User

• Diagnostic Labs
• Hospitals and Clinics
• Research Centers

Global Central Nervous System (CNS) Biomarker Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/central-nervous-system-cns-biomarkers-market